LRRK2 and Parkinson disease: While exploratory, our study suggests that PRS may not be as relevant for carriers of PD-related pathogenic variants such as GBA p.N370S or LRRK2 p.G2019S and other PD high risk variants on predicting DBS treatment response and may be confounding the PRS analysis results.